Intuitive Surgical develops robotic-assisted surgical systems and associated instruments and accessories. Its da Vinci platform supports minimally invasive procedures, while Ion addresses robotic-assisted bronchoscopy. Intuitive earns revenue from system placements, instruments consumed during procedures, accessories, and service contracts, making recurring procedure volume important to its financial performance.
Intuitive Surgical Inc. (ISRG) has a MarketKingdoms composite score of 66.2 (B), an B-range rating. It ranks 686th of 1,866 covered companies, 31st of 78 in Healthcare (sector average 64.4) and 2nd of 9 in Medical Instruments & Supplies. Scores as of 2026-10-26.
Its strongest lenses are Stock selection at 83 (Healthcare average 79) and Industry opportunity at 82 (Healthcare average 81). Its weakest lenses are Price (valuation) at 17 (sector average 50) and Trend (momentum) at 23 (sector average 50).
| Lens | Type | ISRG | Healthcare average | Medical Instruments & Supplies average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 82 | 81 | 82 | 77th |
| Stock selection | Research signal | 83 | 79 | 78 | 71st |
| KPI momentum | Research signal | 78 | 78 | 76 | 48th |
| Catalyst watch | Research signal | 75 | 74 | 76 | 56th |
| Price (valuation) | Fundamental lens | 17 | 50 | 49 | 10th |
| Expansion (growth) | Fundamental lens | 75 | 50 | 46 | 85th |
| Quality (profitability) | Fundamental lens | 73 | 50 | 46 | 81st |
| Trend (momentum) | Fundamental lens | 23 | 50 | 36 | 19th |
The most recent call analysed was held on 2026-10-20 (fiscal 2026 Q3). After it the composite moved from 74.1 to 81.8. MarketKingdoms checks what management promised on each call against what it later delivered.
The composite at the time of each event; today's composite is 66.2.
The stock's valuation gap is -11.5%: its price is below the path its market, sector and industry moves explain (undervalued versus the model path). Factor sensitivity: market beta 1.05, sector beta 0.54, industry beta 0.43; the factor model explains 26% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| ResMed Inc. (RMD) | 67.5 | B | +6.1% |
| West Pharmaceutical Services Inc. (WST) | 65.0 | B | -25.9% |
| Becton Dickinson & Co. (BDX) | 64.4 | B | -4.6% |
| Baxter International Inc. (BAX) | 61.7 | B- | -0.9% |
| Alcon Inc. (ALC) | 61.1 | B- | -14.7% |
| Align Technology Inc. (ALGN) | 60.2 | B- | -17.5% |
| The Cooper Companies Inc. (COO) | 56.7 | C+ | -20.6% |
| Medline Inc. (MDLN) | 53.8 | C+ | -12.2% |
Intuitive Surgical Inc. financial statements · Healthcare sector ranking · Medical Instruments & Supplies industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.